drugset / Trial / NCT01838876
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
Timeline
- Start
- 2013-04-29
- Primary completion
- 2015-07-27
- Completion
- 2015-07-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cariprazine | Small molecule | 1.5 mg | Oral |
| Subject | Cariprazine | Small molecule | 3 mg | Oral |
| Subject | Cariprazine | Small molecule | 4.5 mg | Oral |
| Background | Bupropion | Small molecule | — | — |
| Background | Citalopram | Small molecule | — | — |
| Background | Desvenlafaxine | Other / unclassified | — | — |
| Background | Duloxetine | Small molecule | — | — |
| Background | Escitalopram | Small molecule | — | — |
| Background | Fluoxetine | Small molecule | — | — |
| Background | Paroxetine | Small molecule | — | — |
| Background | Sertraline | Small molecule | — | — |
| Background | Venlafaxine | Small molecule | — | — |
| Background | Vilazodone | Small molecule | — | — |